The Online Investor
Aethlon Medical Inc (AEMD)

Aethlon Medical is a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The Aethlon Hemopurifier (Hemopurifier) is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies.
Company Name: 
Aethlon Medical Inc
Website: 
www.aethlonmedical.com
Sector: 
Medical Instruments & Supplies
Number of ETFs Holding AEMD: 
1
Total Market Value Held by ETFs: 
$30138
Total Market Capitalization: 
$4.00M
% of Market Cap. Held by ETFs: 
0.75%
Quotes delayed 20 minutes

Email EnvelopeFree AEMD Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Aethlon Medical Inc (AEMD) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.